Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection

Cell Rep. 2023 Feb 28;42(2):112075. doi: 10.1016/j.celrep.2023.112075. Epub 2023 Jan 27.

Abstract

Booster immunizations and breakthrough infections can elicit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant neutralizing activity. However, the durability of the neutralization response is unknown. We characterize the sensitivity of BA.1, BA.2, BA.2.75, BA.4/BA.5, BF.7, BQ.1.1, and XBB against neutralizing antibodies from vaccination, hybrid immunity, and breakthrough infections 4-6 months after vaccination and infection. We show that a two-dose CoronaVac or a third-dose ZF2001 booster elicits limited neutralization against Omicron subvariants 6 months after vaccination. Hybrid immunity as well as Delta, BA.1, and BA.2 breakthrough infections induce long-term persistence of the antibody response, and over 70% of sera neutralize BA.1, BA.2, BA.4/BA.5, and BF.7. However, BQ.1.1 and XBB, followed by BA.2.75, are more resistant to neutralization, with neutralizing titer reductions of ∼9- to 41-fold, ∼16- to 63-fold, and ∼4- to 25-fold, respectively. These data highlight additional vaccination in CoronaVac- or ZF2001-vaccinated individuals and provide insight into the durability of neutralization against Omicron subvariants.

Keywords: CP: Immunology; CP: Microbiology; Omicron subvariants; booster vaccination; breakthrough infection; hybrid immunity; immune evasion; neutralization.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Breakthrough Infections*
  • COVID-19* / prevention & control
  • Humans
  • SARS-CoV-2

Substances

  • ZF2001 COVID-19 vaccine
  • sinovac COVID-19 vaccine
  • Antibodies, Neutralizing
  • Antibodies, Viral